SCIENTIFIC PROGRAMME
Thursday, april 25
9:30-11:30 - Educational course on psoriasis
Chairs: Esteban Dauden (Spain) & Luigi Naldi (Italy)
1. Genetics/pathogenesis - Paola di Meglio (UK)
2. Comorbidities - Tiago Torres (Portugal)
3. Topical therapy - Rolland Gyulai (Hungary)
4. Non-biologic systemic therapy - Paola Cardenas (Colombia)
5. Biologic systemic therapy - David Moreno (Spain)
11:30-12:30 Satellite Symposia
12.30-14.00 Welcome reception
14.00-14:10 – Congress Opening:
Fondation René Touraine Welcome and update on SPIN
14:10-16.00 – Plenary 1: Genetics and pathogenesis in psoriasis and atopic dermatitis
Chairs: Pedro Herranz (Spain) & Georg Stingl (Austria)
1. Genetics in psoriasis and atopic dermatitis - Jonathan Barker (UK)
2. Genetics and immunopathogenesis of pustular variants of psoriasis - Hervé Bachelez (France)
3. Autoimmunity vs autoinflammation in psoriasis - Georg Stingl (Austria)
4. Atopic dermatitis pathogenesis and differences and similarities from psoriasis - Emma Guttman-Yassky (US)
16.00-16.30 – Break & Discussed E-Posters
16.30-18.00 – Focus Session 1: Epidemiology and registries
Chairs: Paula Seijo-Dávila (Spain) & Luigi Naldi (Italy)
1. Registries in dermatology: strengths and learning points - Phyllis Spuls (Netherlands)
2. Epidemiology of major inflammatory skin diseases anno 2019 - Luigi Naldi (Italy)
3. Epidemiology of major inflammatory skin diseases in emerging countries - Alur Kumar (India)
4. Comorbidity occurrence in major inflammatory skin diseases - Alexander Egeberg (Denmark)
FREE COMMUNICATIONS:
P001
SAFETY EVENTS OCCURRING AMONG PATIENTS EXPOSED TO IXEKIZUMAB IN THE CORRONA PSORIASIS REGISTRY
E.Grace, B.Zhu , W.Malley , J.O’Brien , R.Magner , N.Agada , G.Gallo * , T.Bhutani (Indianapolis, United States)
P002
NUMBER NEEDED TO TREAT AND COST PER RESPONDER FOR FLEXIBLE ADALIMUMAB DOSING IN THE TREATMENT OF PSORIASIS IN PATIENTS WITH SUBOPTIMAL RESPONSE TO 40MG EVERY OTHER WEEK DOSING
L. J.Savage *, V.Garcia-Horton , J.Li , L.Yin , K. A.Betts , B.Calimlim (Leeds, United Kingdom)
P003
RESPONSE TO ADALIMUMAB IN PATIENTS WITH PLAQUE PSORIASIS BY ASSOCIATED MANIFESTATIONS: ANALYSES FROM THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGICS AND IMMUNOMODULATORS REGISTER
L. J.Savage *, D.Dasgupta , O.Reyes-Servin , B.Calimlim (Leeds, United Kingdom)
16.30-18.00 – Focus Session 2: Advances in target-oriented therapy
Chairs: Romana Ceovic (Croatia) & Skaidra Valiukeviciene (Lithuania)
1. Psoriasis - Brian Kirby (Ireland)
2. Psoriatic arthritis - Wolf-Henning Boehncke (Switzerland)
3. Biomarkers in atopic dermatitis - Emma Guttman-Yassky (US)
FREE COMMUNICATIONS:
P004
GUSELKUMAB DEMONSTRATES SUPERIOR LONG-TERM RESPONSES COMPARED WITH SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE ECLIPSE TRIAL
K.Reich *, A.Armstrong , A.Blauvelt , S.Li , M.-C.Hsu , S.Flavin , B.Randazzo , R.Langley (Hamburg, Germany)
P005
LONG-TERM SAFETY OF IXEKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: RESULTS FROM MORE THAN 17000 PATIENT-YEARS OF EXPOSURE
C. E.Griffiths *, M. G.Lebwohl , A.Blauvelt , K.Reich , M.Gooderham , T.Terui , N.Agada , W.Xu , G.Gallo (Manchester, United Kingdom)
P006
IMMEDIATE ONSET OF ACTION OF BRODALUMAB COMPARED WITH USTEKINUMAB: RESULTS FROM THE PHASE 3 AMAGINE-2 AND -3 STUDIES
S.Philipp *, J.Hansen , V.Schultz Nielsen , A.Chiricozzi (Berlin, Germany)
P018
ADALIMUMAB MONOTHERAPY VS. ADALIMUMAB AND METHOTREXATE COMBINATION THERAPY IN PSORIASIS: FIRST-YEAR RESULTS ON DRUG SURVIVAL, EFFECTIVENESS, SAFETY AND IMMUNOGENICITY
Gayle Van Der Kraaij (Netherlands)
P019
A CASE SERIES OF DUPILUMAB IN COMBINATION WITH OTHER BIOLOGIC THERAPIES IN SEVEN PATIENTS
Hermenio Lima (Canada)
Friday, April 26
08.30-10.00 – Focus Session 3: Autoinflammation and autoimmunity
Chairs: Lara Ferrandiz (Spain) & Richard Warren (UK)
1. Autoimmunity in psoriasis - Jörg Prinz (Germany)
2. Live imaging of cutaneous immune-responses - Kenji Kabashima (Japan)
3. IL-4Rα Blockade Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis - Chris Callewaert (Belgium)
4. Autoinflammation and autoimmunity in psoriasis vs hidradenitis suppurativa - Antonio Martorell (Spain)
FREE COMMUNICATIONS:
P007
THE ROLE OF NEUROIMMUNE INTERACTION IN PATHOPHYSIOLOGY OF GRANULOMATOUS ROSACEA
E.Hong *, K.Kim (Gyeonggi-do, Korea, Republic Of)
P008
ROLE OF KERATIN 24 IN HUMAN EPIDERMAL KERATINOCYTES
M.Zheng *, M.Min , X.Man (Hangzhou, China)
08.30-10.00 – Focus Session 4: Beyond the skin
Chairs: Paolo Gisondi (Italy), Stefano Piaserico (Italy)
1. Psychological and psychiatric comorbidities in major inflammatory skin diseases - Marta Garcia-Bustinduy (Spain)
2. Hepatic and musculoskeletal disease in psoriasis - Paolo Gisondi (Italy)
3. Cardiovascular comorbidities in major inflammatory skin diseases - Stefano Piaserico (Italy)
FREE COMMUNICATIONS:
P009
THERAPEUTIC PATIENT EDUCATION AND SELF-MANAGEMENT SUPPORT FOR PATIENTS WITH PSORIASIS – A LIVING SYSTEMATIC REVIEW AND META-ANALYSIS
C.Dressler , M.Zidane , L.Grine , P.Galdas , J.Lambert , A.Nast * (Berlin, Germany)
P010
DEVELOPMENT OF A PATIENT CHARTER FOR PEOPLE LIVING WITH CONDITIONS, DISEASES OR TRAUMAS INVOLVING THE SKIN
A.Sivanand , K.Andrews-Clay * (Ottawa, Canada)
P020
MITOCHONDRIAL FUNCTION IN PSORIASIS AND INSULIN RESISTANCE: A PILOT STUDY
Alejandra VILLARREAL-MARTINEZ (Mexico)
P021
SAFETY AND EFFECTIVENESS OF USTEKINUMAB IN PSORIATIC ARTHRITIS. A MULTICENTER
STUDY
Ana AZUAGA-PINANGO (Spain)
10.00-10.30 – Break & Discussed E-Posters
10.30-12.30 – Plenary 2: Novelties in therapeutics
Chairs: Pablo de la Cueva (Spain) & Thomas Luger (Germany)
1. Anti TNF and small molecules in psoriasis - Sandra Philipp (Germany)
2. Anti IL17 in psoriasis - Carle Paul (France)
3. Anti p40/anti p19 in psoriasis - Kristian Reich (Germany)
4. New molecules in atopic dermatitis - Diamant Thaçi (Germany)
5. Which drug for which patient ? - Emilie Sbidian (France)
6. Latest trials on the effect of biotherapy on cardiovascular disease in psoriasis - Nehal Mehta (US)
12.30-14.00 Lunch break / Satellite Symposia
14.00-15.30 Focus Session 5 - Topical treatments and physical modalities of treatment
Chairs: José Manuel Carrascosa (Spain) & Lajos Kemeny (Hungary)
1. Topical therapy in psoriasis and atopic dermatitis - José Manuel Carrascosa (Spain)
2. UVB in psoriasis and atopic dermatitis - Piergiacomo Calzavara (Italy)
3. Innovative phototherapeutic approaches in psoriasis and atopic dermatitis - Lajos Kemeny (Hungary)
4. Physical treatment modalities in hidradenitis suppurativa - Errol Prens (Netherlands)
FREE COMMUNICATIONS:
P023
CO-ENCAPSULATION OF IMMUNO-ACTIVE AND ANTI-INFLAMMATORY MOLECULES
IN A PICKERING EMULSION FOR PSORIASIS AND ATOPIC DERMATITIS THERAPEUTIC APPROACH
Maxime SINTES (France)
14.00-15.30 – Focus Session 6 – Advances and latest insights in non biologic systemic therapeutic agents in psoriasis and atopic dermatitis
Chairs: Raquel Rivera (Spain) & Martine Bagot (France)
1. Fumarates / Vitamin A Derivatives - Peter van de Kerkhof (Netherlands)
2. CsA / MMF /Azathioprine - César Gonzalez (Colombia)
3. MTX - Rolland Gyulai (Hungary)
4. Small molecules, apremilast and beyond - Richard Langley (Canada)
FREE COMMUNICATIONS:
P011
UPADACITINIB IMPROVED PATIENT-REPORTED PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
C.-H.Hong *, T.Wu , B.Calimlim , H.Teixeira , M.de Bruin-Weller (Surrey, Canada)
P012
DRUG SURVIVAL OF FUMARIC ACID ESTERS (FAE) FOR MODERATE-TO-SEVERE PSORIASIS IN A GERMAN PSORIASIS REGISTRY: PSOBEST
K.Reich , M. A.Radtke , C.Sorbe *, M.Augustin (Hamburg, Germany)
P013
INTERIM ANALYSIS OF SKILL NON-INTERVENTIONAL STUDY: DIMETHYLFUMARATE IN LONG-TERM TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ROUTINE PRACTICE – CHARACTERISATION OF PATIENT POPULATION IN COMPARISON WITH PSOBEST AND PSOHEALTH
M.Augustin , C.Sorbe *, A.Kirsch , S.Diemert (Hamburg, Germany)
15.30-16.00 – Break & Discussed E-Posters
16.00-18.00: SPIN Forum
Chairs: Louis Dubertret (France) & Chih-ho Hong (Canada)
1. Limitations on access to conventional/biologic therapy around the world - Maria Lorna Frez (Philippines), Nejib Doss (Tunisia),
2. Screening and follow up for conventional/biologic therapy - Carlos Muñoz (Spain), Emad Elgamal (Egypt)
3. Infections in patients under immunosuppressive drugs: learning from difference - Marta Ferran (Spain), Fernando Valenzuela (Chile), Ibrahim Almukahal (Libya)
Discussion
16.00-18.00: How do I manage?
Chairs: Luis Puig (Spain), Peter Van de Kerkhof (Netherlands), Marta Garcia-Bustinduy (Spain)
1. Pregnancy - Juan Raul Castro (Colombia)
2. Childhood psoriasis - Marieke Seyger (Netherlands)
3. Chronic hepatic disease - Eva Vilarrasa (Spain)
4. Chronic infections - Fatimata Ly (Senegal)
5. Nail psoriasis - Bertrand Richert (Belgium)
6. Recalcitrant atopic dermatitis - Esther Serra (Spain)
Saturday, April 27
08.30-10.00 – Focus Session 7: Treatment goals/guidelines in major inflammatory skin diseases
Chairs: Luis Puig (Spain), Kenji Kabashima (Japan)
1. Treatment goals in psoriasis - Ulrich Mrowietz (Germany)
2. Guideline variability across countries - Jashin Wu (US)
3. Drug survival - Elke de Jong (Netherlands)
4. Treatment outcomes and goals in atopic dermatitis - Esther Serra (Spain)
08.30-10.00 – Focus Session 8: Individualized therapy in major inflammatory skin diseases
Chairs: Jan Gutermuth (Belgium) & Ronald Vender (Canada)
1. Treat to target - Alexander Nast (Germany)
2. Transitioning between biologics - Ronald Vender (Canada)
3. Combination therapy - Pablo Coto (Spain)
4. Therapeutic drug monitoring in biologics - Ann Gils (Belgium)
FREE COMMUNICATIONS:
P014
IDENTIFICATION OF CLINICAL AND BIOMARKER PARAMETERS ASSOCIATED WITH LONG-TERM MAINTENANCE OF PASI 90 RESPONSE FOLLOWING GUSELKUMAB TREATMENT WITHDRAWAL IN PSORIASIS
X.Liu , P.Branigan , Y.Chen , B.Scott , M.Banaszewska , P.McGovern , Z.Yao , S. Fakharzadeh *, S.Li , Y.Wasfi , M.Song , K.Campbell , E. J.Muñoz-Elías (Spring House, United States)
P015
DEFINING A MINIMAL EFFECTIVE SERUM TROUGH CONCENTRATION OF SECUKINUMAB IN PSORIASIS: A STEP TOWARDS PERSONALIZED THERAPY
R.Soenen , E.Meulewaeter , L.Grine , N.Van den Berghe , B.Els , R.Speeckaert , S.Lanssens , L.Temmerman , J.Lambert *, A.Gils (Ghent, Belgium)
P024
FOLLOW-UP OF PATIENTS WITH PSORIASIS IN COMMUNITY PHARMACY
Joana FERREIRA (Portugal)
10.00-10.30 – Break & Discussed E-Posters
10.30-12.30 – Plenary 3: Outcomes in psoriasis
Chairs: Jo Lambert (Belgium) & Ulrich Mrowietz (Germany)
1. Intro to value based healthcare, applied to a chronic disease model - Jan Gutermuth (Belgium)
2. Patient relevant outcome measures in psoriasis (IDEOM) - Alice Gottlieb (US)
3. Measures to treat psoriasis beyond drugs - Ulrich Mrowietz (Germany)
4. Can we justify the cost of a value based psoriasis approach? - Matthias Augustin (Germany)
12.30-14.00 Lunch break / Satellite Symposia
14.00-15.30 – Focus Session 9: Empowering HCPs in leadership and management
Chair: Jo Lambert (Belgium)
1. How to use resources effectively? - Jo Lambert (Belgium)
2. Establishing Interdisciplinary Teams for Best Practice Patient Care - Christine Bundy (UK)
3. How to deal with non-adherence in patients? - Rachael Thorneloe (UK)
4. Shared decision making in chronic illnesses - Phyllis Spuls (Netherlands)
FREE COMMUNICATIONS:
P016
PLAQUE PSORIASIS IN HARD-TO-TREAT BODY LOCATIONS: CLINICAL MANAGEMENT AND HEALTH CARE RESOURCE UTILIZATION OF PATIENTS TREATED WITH BIOLOGIC AGENTS
M. Penney *, W.Gulliver , S.Gulliver , M.DiBattista , A.Kavanagh , S.Randell , R.Power , N.Gladney , H.Wang , D.MacDonald , S.Montmayeur , R.Burge (St. John's, Canada)
14.00-15.30 – Focus Session 10: Special situations: children, pregnancy, old age, cancer patients in major inflammatory skin diseases
Chairs: Isabel Belinchon (Spain), Emad Elgamal (Egypt)
Introduction
1. Paradoxical reactions - Anna Lopez (Spain)
2. Scalp and genital psoriasis - Maria Lorna Frez (Philippines)
3. Old age/cancer patients - Satish Lubeek (Netherlands)
FREE COMMUNICATIONS:
P017
CO-EXISTENCE OF PSORIASIS AND ATOPIC DERMATITIS IN SAME PATIENTS AND FAMILIES
R.konathan *, B. S.papisetty , S. K.alur (Hyderabad, India)
P025
USTEKINUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN PEDIATRIC PATIENTS (≥6 TO <12 YEAR OF AGE): RESULTS FROM CADMUS JR
Sandra PHILIPP (US)
P026
IMMUNOBIOLOGICS IN PREGNANCY: CASE REPORTS FROM LATIN AMERICA
Luna AZULAY-ABULAFIA (Brazil)
15.30-16.00 – Break & Discussed E-Posters
16.00-17.45 - Plenary 4: Medical need and Challenges in other Inflammatory Dermatoses & Late Abstracts
FREE COMMUNICATIONS:
P022
EVALUATION OF QUALITY OF LIFE IN PATIENTS WITH VITILIGO BY MEANS OF QUESTIONNAIRE VITIQOL
Anber ANCEL TANAKA (Brazil)
17.45-18.00 Closing remarks